Press Releases 2025 2024 2023 2022 2021 2020 2019 all October 1, 2019 Dyne Therapeutics Announces Appointment of Joshua Brumm as President and Chief Executive Officer September 23, 2019 Dyne Therapeutics Announces Support for ReSolve Natural History Study of Patients with Facioscapulohumeral Muscular Dystrophy (FSHD) August 19, 2019 Dyne Therapeutics Expands Board of Directors with Appointment of Lawrence Klein June 28, 2019 Dyne Therapeutics Appoints Catherine Stehman-Breen to its Board of Directors June 17, 2019 Dyne Therapeutics Announces Support for END-DM1 Natural History Study of Patients with Myotonic Dystrophy Type 1 (DM1) June 13, 2019 Dyne Therapeutics Presents Nonhuman Primate Proof of Concept Data on FORCE™ Therapeutic Platform at International Myotonic Dystrophy Consortium Meeting (IDMC-12) April 3, 2019 Dyne Therapeutics Launches with $50 Million Series A to Develop Targeted Therapies for Muscle Diseases
